FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320801251> ?p ?o ?g. }

• W4320801251 endingPage "591" @default.
• W4320801251 startingPage "589" @default.
• W4320801251 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2003The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen BRETT S. CARVER, CALEB B. BOZEMAN, B.J. WILLIAMS, and DENNIS D. VENABLE BRETT S. CARVERBRETT S. CARVER More articles by this author , CALEB B. BOZEMANCALEB B. BOZEMAN More articles by this author , B.J. WILLIAMSB.J. WILLIAMS More articles by this author , and DENNIS D. VENABLEDENNIS D. VENABLE More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)63959-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the prevalence and relationship of serum prostate specific antigen (PSA) levels in a screening population of men diagnosed with National Institutes of Health (NIH) category IV prostatitis. Materials and Methods: In September of 2001, 300 men were randomly selected from our prostate cancer awareness screening program to be evaluated for NIH category IV prostatitis. After informed consent was obtained all patients completed the NIH prostate cancer awareness survey and had a serum sample obtained for PSA before examination. Expressed prostatic secretions were obtained from 227 of the 300 participants. Patients were classified according to findings on examination of the expressed prostatic secretions. The records were entered into our data base and subsequently reviewed. Results: The prevalence of NIH category IV prostatitis was 32.2% in our population of men. Patient age, American Urological Association symptom scores and clinical prostate gland size did not differ between men with or without evidence of prostatitis on expressed prostatic secretion examination. Men with NIH category IV prostatitis had a mean serum PSA level of 2.3 which was significantly higher (p <0.0004) than those without prostatitis (mean PSA 1.4). Conclusions: These data suggest that NIH category IV prostatitis is fairly prevalent (32.2%) among men in the general population who present for prostate cancer screening and appears to contribute to increased serum PSA levels in some men. References 1 : Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999; 54: 229. Google Scholar 2 : Questionnaire survey of urologists and primary care physicians’ diagnostics and treatment practices for prostatitis. Urology1997; 50: 543. Google Scholar 3 : How common is prostatitis? A national survey of physician visits. J Urol1998; 159: 1224. Link, Google Scholar 4 : Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology1998; 51: 578. Google Scholar 5 : Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol1995; 154: 407. Link, Google Scholar 6 : Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate1994; 25: 91. Google Scholar 7 : Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol2000; 164: 1550. Link, Google Scholar 8 : Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol2002; 167: 1723. Link, Google Scholar 9 : Prostatitis. Med Clin North Am1991; 75: 405. Google Scholar 10 : Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol2002; 167: 1363. Google Scholar 11 : Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology1998; 51: 300. Google Scholar 12 : Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst1997; 89: 134. Google Scholar 13 : Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol1999; 162: 2014. Link, Google Scholar From the Department of Urology, Louisiana State University Health Sciences Center, Shreveport, Louisiana© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byTekin A, Yuksel A, Tekin S, Gumrukcu G, Aslan A and Sengor F (2018) Post-Prostatic Massage Examination for Prediction of Asymptomatic Prostatitis in Needle Biopsies: A Prospective StudyJournal of Urology, VOL. 182, NO. 2, (564-569), Online publication date: 1-Aug-2009.SCHAEFFER A, WU S, TENNENBERG A and KAHN J (2018) TREATMENT OF CHRONIC BACTERIAL PROSTATITIS WITH LEVOFLOXACIN AND CIPROFLOXACIN LOWERS SERUM PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 174, NO. 1, (161-164), Online publication date: 1-Jul-2005.PLATZ E and De MARZO A (2018) Epidemiology of Inflammation and Prostate CancerJournal of Urology, VOL. 171, NO. 2S, (S36-S40), Online publication date: 1-Feb-2004.NELSON W, DE MARZO A, DeWEESE T and ISAACS W (2018) THE ROLE OF INFLAMMATION IN THE PATHOGENESIS OF PROSTATE CANCERJournal of Urology, VOL. 172, NO. 5S, (S6-S12), Online publication date: 1-Nov-2004. Volume 169Issue 2February 2003Page: 589-591 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostate-specific antigen, mass screeningprostatic neoplasmsNational Institutes of Health (U.S.)prostatitisMetricsAuthor Information BRETT S. CARVER More articles by this author CALEB B. BOZEMAN More articles by this author B.J. WILLIAMS More articles by this author DENNIS D. VENABLE More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4320801251 created "2023-02-15" @default.
• W4320801251 creator A5042632487 @default.
• W4320801251 creator A5042883465 @default.
• W4320801251 creator A5075105283 @default.
• W4320801251 creator A5081646632 @default.
• W4320801251 date "2003-02-01" @default.
• W4320801251 modified "2023-09-27" @default.
• W4320801251 title "The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen" @default.
• W4320801251 cites W1973214716 @default.
• W4320801251 cites W2016018496 @default.
• W4320801251 cites W2021550978 @default.
• W4320801251 cites W2061633878 @default.
• W4320801251 cites W2073906111 @default.
• W4320801251 cites W2085719058 @default.
• W4320801251 cites W2098233382 @default.
• W4320801251 cites W2110364065 @default.
• W4320801251 cites W2139366934 @default.
• W4320801251 cites W2157254022 @default.
• W4320801251 cites W2165559381 @default.
• W4320801251 cites W4244248932 @default.
• W4320801251 cites W4292688124 @default.
• W4320801251 doi "https://doi.org/10.1016/s0022-5347(05)63959-6" @default.
• W4320801251 hasPublicationYear "2003" @default.
• W4320801251 type Work @default.
• W4320801251 citedByCount "55" @default.
• W4320801251 countsByYear W43208012512012 @default.
• W4320801251 countsByYear W43208012512013 @default.
• W4320801251 countsByYear W43208012512015 @default.
• W4320801251 countsByYear W43208012512016 @default.
• W4320801251 countsByYear W43208012512019 @default.
• W4320801251 countsByYear W43208012512020 @default.
• W4320801251 countsByYear W43208012512021 @default.
• W4320801251 crossrefType "journal-article" @default.
• W4320801251 hasAuthorship W4320801251A5042632487 @default.
• W4320801251 hasAuthorship W4320801251A5042883465 @default.
• W4320801251 hasAuthorship W4320801251A5075105283 @default.
• W4320801251 hasAuthorship W4320801251A5081646632 @default.
• W4320801251 hasConcept C121608353 @default.
• W4320801251 hasConcept C126322002 @default.
• W4320801251 hasConcept C126894567 @default.
• W4320801251 hasConcept C2775941076 @default.
• W4320801251 hasConcept C2776235491 @default.
• W4320801251 hasConcept C2780192828 @default.
• W4320801251 hasConcept C2780524745 @default.
• W4320801251 hasConcept C2781406297 @default.
• W4320801251 hasConcept C2908647359 @default.
• W4320801251 hasConcept C29456083 @default.
• W4320801251 hasConcept C512399662 @default.
• W4320801251 hasConcept C71924100 @default.
• W4320801251 hasConcept C99454951 @default.
• W4320801251 hasConceptScore W4320801251C121608353 @default.
• W4320801251 hasConceptScore W4320801251C126322002 @default.
• W4320801251 hasConceptScore W4320801251C126894567 @default.
• W4320801251 hasConceptScore W4320801251C2775941076 @default.
• W4320801251 hasConceptScore W4320801251C2776235491 @default.
• W4320801251 hasConceptScore W4320801251C2780192828 @default.
• W4320801251 hasConceptScore W4320801251C2780524745 @default.
• W4320801251 hasConceptScore W4320801251C2781406297 @default.
• W4320801251 hasConceptScore W4320801251C2908647359 @default.
• W4320801251 hasConceptScore W4320801251C29456083 @default.
• W4320801251 hasConceptScore W4320801251C512399662 @default.
• W4320801251 hasConceptScore W4320801251C71924100 @default.
• W4320801251 hasConceptScore W4320801251C99454951 @default.
• W4320801251 hasIssue "2" @default.
• W4320801251 hasLocation W43208012511 @default.
• W4320801251 hasOpenAccess W4320801251 @default.
• W4320801251 hasPrimaryLocation W43208012511 @default.
• W4320801251 hasRelatedWork W1980188241 @default.
• W4320801251 hasRelatedWork W2038565121 @default.
• W4320801251 hasRelatedWork W2049045266 @default.
• W4320801251 hasRelatedWork W2148869351 @default.
• W4320801251 hasRelatedWork W2384969752 @default.
• W4320801251 hasRelatedWork W2897445903 @default.
• W4320801251 hasRelatedWork W2946218464 @default.
• W4320801251 hasRelatedWork W3129209394 @default.
• W4320801251 hasRelatedWork W4281788288 @default.
• W4320801251 hasRelatedWork W2614794076 @default.
• W4320801251 hasVolume "169" @default.
• W4320801251 isParatext "false" @default.
• W4320801251 isRetracted "false" @default.
• W4320801251 workType "article" @default.